GlucoTrack unit Lōkahi Therapeutics expands ai² PIPELINE to external sponsor Innovate GBM
GCTK•Work to focus on glioblastoma and other brain tumors
The work will focus on glioblastoma and other brain tumors. Innovate GBM will decide independently whether to pursue any identified assets.
The move positions ai² PIPELINE as a revenue-generating platform, extending beyond internal discovery across Lōkahi’s 14 university collaborations.
Lōkahi Therapeutics secures first external engagement
GlucoTrack’s subsidiary Lōkahi Therapeutics secured its first external engagement for its proprietary ai² PIPELINE asset-identification platform.
Innovate GBM engaged two ai² PIPELINE teams to identify brain tumor therapeutic assets for potential licensing and development.
